CoChat
Sign Up
Cited by 138Radiopharmaceutical Chemistry and ApplicationsMedical Imaging Techniques and ApplicationsMonoclonal and Polyclonal Antibodies Research

Monoclonal antibody-based molecular imaging strategies and theranostic opportunities

Open access
Dammes, Niels, Peer, Dan·2020·Theranostics
DOI 10.7150/thno.37443PMC PMC6929980
Open this paper in CoChat — free accountOpen PDF

Abstract

Molecular imaging modalities hold great potential as less invasive techniques for diagnosis and management of various diseases.Molecular imaging combines imaging agents with targeting moieties to specifically image diseased sites in the body.Monoclonal antibodies (mAbs) have become increasingly popular as novel therapeutics against a variety of diseases due to their specificity, affinity and serum stability.Because of the same properties, mAbs are also exploited in molecular imaging to target imaging agents such as radionuclides to the cell of interest in vivo.Many studies investigated the use of mAb-targeted imaging for a variety of purposes, for instance to monitor disease progression and to predict response to a specific therapeutic agent.Herein, we highlighted the application of mAb-targeted imaging in three different types of pathologies: autoimmune diseases, oncology and cardiovascular diseases.We also described the potential of molecular imaging strategies in theranostics and precision medicine.Due to the nearly infinite repertoire of mAbs, molecular imaging can change the future of modern medicine by revolutionizing diagnostics and response prediction in practically any disease.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.7150/thno.37443

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Antibody fragments have tunable pharmacokinetic properties and the unique ability to detect biomarkers with high affinity and specificity in vitro and in vivo, making them excellent agents for tumor imaging.

    “Their tunable pharmacokinetic properties together with the unique ability to detect with high-affinity and specificity biomarkers in vitro and in vivo, making them excellent agents for tumor imaging [184,185].”

    From Evolution of Escherichia coli Expression System in Producing Antibody Recombinant Fragments (2020) · cites this paper as [185]

    In “Use of antibody fragments for decreased background signal” (page not supplied), the review describes fragments with different in vivo kinetics and clearance rates and gives examples of their use in cancer imaging. It also describes high-affinity affibodies as useful for PET imaging, but does not establish the claimed high-affinity, specific biomarker detection both in vitro and in vivo; it cautions that the highest affinity may not be best for tumor imaging. (LLM, conf=0.83)

    Experimental — accuracy not yet measured

  • In recent years, antibody fragments have achieved encouraging successes as theranostic agents contributing to the development of new personalized and more effective medicine.

    “In recent years, antibody fragments have also achieved encouraging successes as theranostic agents contributing to the development of new personalized and more effective medicine.”

    From Evolution of Escherichia coli Expression System in Producing Antibody Recombinant Fragments (2020) · cites this paper as [185]

    The section ‘Use of antibody fragments for decreased background signal’ gives examples of antibody fragments used in molecular imaging, and the Conclusion says theranostics holds promise for personalized treatment and precision medicine (page numbers unavailable). The paper does not establish that antibody fragments have already achieved successes as theranostic agents or made medicine more effective; it presents much of that benefit as future potential. (LLM, conf=0.85)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 140

  1. [1]Frankel R Centennial of Rontgen's Discovery of X-rays West J Med 1995 164 497 501 PMC1303625 8764624
  2. [2]Rubin GD Computed Tomography: Revolutionizing the Practice of Medicine for 40 Years Radiology 2014 273 S45 74 25340438
  3. [3]Morris P Perkins A Diagnostic imaging Lancet 2012 379 1525 33 22516558
  4. [4]Radiology ES of Medical imaging in personalised medicine: a white paper of the research committee of the European Society of Radiology (ESR) Insights Imaging 2011 2 621 22347981 PMC3259336
  5. [5]Pysz MA Gambhir SS Willmann JK Molecular imaging: current status and emerging strategies Clin Radiol 2010 65 500 16 20541650 PMC3150531
  6. [6]Nasongkla N Bey E Ren J Multifunctional Polymeric Micelles as Cancer-Targeted, MRI-Ultrasensitive Drug Delivery Systems 2006; 6: 2427-30 17090068
  7. [7]Blanco E Kessinger CW Sumer BD Gao J Multifunctional Micellar Nanomedicine for Cancer Therapy Exp Biol Med 2009 234 123 31 PMC2864888 19064945
  8. [8]S Liu, D.S. Edwards Bifunctional Chelators for Therapeutic Lanthanide Radiopharmaceuticals 2000 12 653 11170362
  9. [10]Mansour N Dumulon-Perreault V Ait-Mohand S Paquette M Lecomte R Guérin B Impact of dianionic and dicationic linkers on tumor uptake and biodistribution of [ 64 Cu]Cu/NOTA peptide-based gastrin-releasing peptide receptors antagonists J Label Compd Radiopharm 2017 60 200 12 28129446
  10. [11]James ML Gambhir SS A Molecular Imaging Primer: Modalities, Imaging Agents, and Applications Physiol Rev 2012 92 897 965 22535898
  11. [12]Kim D Jeong YY Jon S A Drug-Loaded Aptamer-Gold Nanoparticle Bioconjugate for Combined CT Imaging and Therapy of Prostate Cancer ACS Nano 2010 4 3689 96 20550178
  12. [14]Johansen ML Gao Y Hutnick MA Quantitative Molecular Imaging with a Single Gd-Based Contrast Agent Reveals Specific Tumor Binding and Retention in vivo Anal Chem 2017 89 5932 9 28481080 PMC5603198
  13. [15]Weber J Beard PC Bohndiek SE Contrast agents for molecular photoacoustic imaging Nat Methods 2016 13 639 50 27467727
  14. [16]Filippi M Garello F Pasquino C Indocyanine green labeling for optical and photoacoustic imaging of mesenchymal stem cells after in vivo transplantation J Biophotonics 2019 12 e201800035 30471202
  15. [17]Wilson KE Bachawal S V Abou-Elkacem L Spectroscopic Photoacoustic Molecular Imaging of Breast Cancer using a B7-H3-targeted ICG Contrast Agent Theranostics 2017 7 1463 76 28529630 PMC5436506
  16. [18]Adams A Mourik JEM van der Voort M Estimation of detection limits of a clinical fluorescence optical mammography system for the near-infrared fluorophore IRDye800CW: phantom experiments J Biomed Opt 2012 17 0760221 22894505
  17. [19]Hemmer E Benayas A Légaré F Vetrone F Exploiting the biological windows: current perspectives on fluorescent bioprobes emitting above 1000 nm Nanoscale Horizons 2016 1 168 84 32260620
  18. [20]Li C Xu X McMahon N Alhaj Ibrahim O Sattar HA Tichauer KM Paired-Agent Fluorescence Molecular Imaging of Sentinel Lymph Nodes Using Indocyanine Green as a Control Agent for Antibody-Based Targeted Agents Contrast Media Mol Imaging 2019 2019 1 13 PMC6335824 30718985
  19. [21]Ryman JT Meibohm B Pharmacokinetics of Monoclonal Antibodies CPT pharmacometrics Syst Pharmacol 2017 6 576 88 28653357 PMC5613179
  20. [22]Waaijer SJH Kok IC Eisses B Molecular Imaging in Cancer Drug Development J Nucl Med 2018 29371402
  21. [23]Schatz DG Ji Y Recombination centres and the orchestration of V(D)J recombination Nat Rev Immunol 2011 11 251 63 21394103
  22. [24]De Silva NS Klein U Dynamics of B cells in germinal centres Nat Rev Immunol 2015 15 137 48 25656706 PMC4399774
  23. [25]Tabasinezhad M Talebkhan Y Wenzel W Rahimi H Omidinia E Mahboudi F Trends in therapeutic antibody affinity maturation: From in-vitro towards next-generation sequencing approaches Immunol Lett 2019 212 106 13 31247224
  24. [26]Hwang WYK Foote J Immunogenicity of engineered antibodies Methods 2005 36 3 10 15848070
  25. [27]Harding FA Stickler MM Razo J DuBridge RB The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions MAbs 2010 2 256 65 20400861 PMC2881252
  26. [28]Slastnikova TA Ulasov A V Rosenkranz AA Sobolev AS Targeted Intracellular Delivery of Antibodies: The State of the Art Front Pharmacol 2018 9 1208 30405420 PMC6207587
  27. [29]Rath T Baker K Dumont JA Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics Crit Rev Biotechnol 2015 35 235 54 24156398 PMC4876602
  28. [30]Moreau M Poty S Vrigneaud J-M MANOTA: a promising bifunctional chelating agent for copper-64 immunoPET Dalt Trans 2017 46 14659 68 28861553
  29. [31]Di Bartolo N Sargeson AM Smith S V New 64Cu PET imaging agents for personalised medicine and drug development using the hexa-aza cage, SarAr Org Biomol Chem 2006 4 3350 17036125
  30. [32]Dearling JLJ Park EJ Dunning P Detection of intestinal inflammation by MicroPET imaging using a 64Cu-labeled anti-β7 integrin antibody Inflamm Bowel Dis 2010 16 1458 66 20186943 PMC2930103
  31. [33]Dearling JLJ Daka A Veiga N Peer D Packard AB Colitis ImmunoPET: Defining Target Cell Populations and Optimizing Pharmacokinetics Inflamm Bowel Dis 2016 22 529 38 26841223
  32. [34]Hein CD Liu X-M Wang D Click chemistry, a powerful tool for pharmaceutical sciences Pharm Res 2008 25 2216 30 18509602 PMC2562613
  33. [35]Oller-Salvia B Kym G Chin JW Rapid and Efficient Generation of Stable Antibody-Drug Conjugates via an Encoded Cyclopropene and an Inverse-Electron-Demand Diels-Alder Reaction Angew Chemie Int Ed 2018 57 2831 4 PMC5861662 29356244
  34. [36]Oller-Salvia B Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction J Vis Exp 2018 139 58066 PMC6235180 30272643
  35. [37]Fujiki K Yano S Ito T A One-Pot Three-Component Double-Click Method for Synthesis of [67Cu]-Labeled Biomolecular Radiotherapeutics Sci Rep 2017 7 1912 28507297 PMC5432496
  36. [38]Da Pieve C Allott L Martins CD Efficient [ 18 F]AlF Radiolabeling of Z HER3:8698 Affibody Molecule for Imaging of HER3 Positive Tumors Bioconjugate Chem 2016 27 1839 49 27357023
  37. [39]Kobayashi H Choyke PL Ogawa M Monoclonal antibody-based optical molecular imaging probes; considerations and caveats in chemistry, biology and pharmacology Curr Opin Chem Biol 2016 33 32 8 27281509 PMC5018422
  38. [40]Jung I-Y Lee J Unleashing the Therapeutic Potential of CAR-T Cell Therapy Using Gene-Editing Technologies Mol Cells 2018 41 717 23 30110720 PMC6125425
  39. [41]Fu R Carroll L Yahioglu G Aboagye EO Miller PW Antibody Fragment and Affibody ImmunoPET Imaging Agents: Radiolabelling Strategies and Applications ChemMedChem 2018 13 2466 78 30246488 PMC6587488
  40. [42]Duranti C Carraresi L Sette A Generation and characterization of novel recombinant anti-hERG1 scFv antibodies for cancer molecular imaging Oncotarget 2018 9 34972 89 30405887 PMC6201861
  41. [43]Lepin EJ Leyton J V Zhou Y An affinity matured minibody for PET imaging of prostate stem cell antigen (PSCA)-expressing tumors Eur J Nucl Med Mol Imaging 2010 37 1529 38 20354850 PMC2903645
  42. [44]Zettlitz KA Tsai W-TK Knowles SM Dual-Modality Immuno-PET and Near-Infrared Fluorescence Imaging of Pancreatic Cancer Using an Anti-Prostate Stem Cell Antigen Cys-Diabody J Nucl Med 2018 59 1398 405 29602820 PMC6126441
  43. [45]Qi S Hoppmann S Xu Y Cheng Z PET Imaging of HER2-Positive Tumors with Cu-64-Labeled Affibody Molecules Mol Imaging Biol 2019 1 10 30617730
  44. [46]Debie P Devoogdt N Hernot S Targeted Nanobody-Based Molecular Tracers for Nuclear Imaging and Image-Guided Surgery Antibodies 2019 8 12 PMC6640687 31544818
  45. [47]Senders ML Hernot S Carlucci G Nanobody-Facilitated Multiparametric PET/MRI Phenotyping of Atherosclerosis JACC Cardiovasc Imaging 2018 S1936-878X: 30753-8 PMC6461528 30343086
  46. [48]Fujimori K Covell DG Fletcher JE Weinstein JN A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier J Nucl Med 1990 31 1191 8 2362198
  47. [49]Xenaki KT Oliveira S van Bergen En Henegouwen PMP Antibody or Antibody Fragments: Implications for Molecular Imaging and Targeted Therapy of Solid Tumors Front Immunol 2017 8 1287 29075266 PMC5643388
  48. [50]Lu F-M Yuan Z PET/SPECT molecular imaging in clinical neuroscience: recent advances in the investigation of CNS diseases Quant Imaging Med Surg 2015 5 433 47 26029646 PMC4426104
  49. [51]Henry KE Dilling TR Abdel-Atti D Edwards KJ Evans MJ Lewis JS Noninvasive 89Zr-Transferrin PET Shows Improved Tumor Targeting Compared with 18F-FDG PET in MYC-Overexpressing Human Triple-Negative Breast Cancer J Nucl Med 2018 59 51 7 28848040 PMC5750524
  50. [52]Snir JA Suchy M Bindseil GA An Aspartyl Cathepsin Targeted PET Agent: Application in an Alzheimer's Disease Mouse Model J Alzheimer's Dis 2018 61 1241 52 29332035
  51. [53]Chen B Zhang W Ji B Ma Q Li D Gao S Integrin αVβ3-targeted SPECT/CT for the assessment of Bevacizumab therapy in orthotopic lung cancer xenografts Oncol Lett 2018 15 4201 6 29541186 PMC5835916
  52. [54]Zhao L Li Y Zhu J Chlorotoxin peptide-functionalized polyethylenimine-entrapped gold nanoparticles for glioma SPECT/CT imaging and radionuclide therapy J Nanobiotechnology 2019 17 30 30782154 PMC6380014
  53. [55]Perik PJ Lub-De Hooge MN Gietema JA Indium-111-Labeled Trastuzumab Scintigraphy in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer J Clin Oncol 2006 24 2276 82 16710024
  54. [56]Zhang HK Chen Y Kang J Prostate-specific membrane antigen-targeted photoacoustic imaging of prostate cancer in vivo J Biophotonics 2018 11 e201800021 29653029 PMC6578595
  55. [57]Okumura K Yoshida K Yoshioka K Photoacoustic imaging of tumour vascular permeability with indocyanine green in a mouse model Eur Radiol Exp 2018 2 5 29708213 PMC5909364
  56. [58]Chen Z-Y Wang Y-X Lin Y Advance of molecular imaging technology and targeted imaging agent in imaging and therapy Biomed Res Int 2014 2014 819324 24689058 PMC3943245
  57. [59]Niu G Zhu L Ho DN Longitudinal bioluminescence imaging of the dynamics of Doxorubicin induced apoptosis Theranostics 2013 3 190 200 23471295 PMC3590588
  58. [60]Stuker F Ripoll J Rudin M Fluorescence molecular tomography: principles and potential for pharmaceutical research Pharmaceutics 2011 3 229 74 24310495 PMC3864234
  59. [61]Lim B Yao Y Huang AL A Unique Recombinant Fluoroprobe Targeting Activated Platelets Allows In vivo Detection of Arterial Thrombosis and Pulmonary Embolism Using a Novel Three-Dimensional Fluorescence Emission Computed Tomography (FLECT) Technology Theranostics 2017 7 1047 61 28435447 PMC5399575
  60. [62]Benitez JA Zanca C Ma J Cavenee WK Furnari FB Fluorescence Molecular Tomography for In vivo Imaging of Glioblastoma Xenografts J Vis Exp 2018 e57448 PMC6100979 29757276
  61. [63]Jin Y-H Hua Q-F Zheng J-J Diagnostic Value of ER, PR, FR and HER-2-Targeted Molecular Probes for Magnetic Resonance Imaging in Patients with Breast Cancer Cell Physiol Biochem 2018 49 271 81 30138940
  62. [64]Cheng VWT Soto MS Khrapitchev AA VCAM-1-targeted MRI Enables Detection of Brain Micrometastases from Different Primary Tumors Clin Cancer Res 2019 25 533 43 30389659
  63. [65]Pan D Williams TA Senpan A Detecting vascular biosignatures with a colloidal, radio-opaque polymeric nanoparticle J Am Chem Soc 2009 131 15522 7 19795893 PMC2826244
  64. [66]Lin J Hu W Gao F Qin J Peng C Lu X Folic acid-modified diatrizoic acid-linked dendrimer-entrapped gold nanoparticles enable targeted CT imaging of human cervical cancer J Cancer 2018 9 564 77 29483962 PMC5820924
  65. [67]Ghaziyani MF Moghaddam MP Shahbazi-Gahrouei D Anti-CD24 bio Modified PEGylated Gold Nanoparticles as Targeted Computed Tomography Contrast Agent Adv Pharm Bull 2018 8 599 607 30607332 PMC6311644
  66. [68]Deshpande N Needles A Willmann JK Molecular ultrasound imaging: current status and future directions Clin Radiol 2010 65 567 81 20541656 PMC3144865
  67. [69]Mancini M Greco A Salvatore G Imaging of thyroid tumor angiogenesis with microbubbles targeted to vascular endothelial growth factor receptor type 2 in mice BMC Med Imaging 2013 13 31 24028408 PMC3848463
  68. [70]Wang L Wang F-S Gershwin ME Human autoimmune diseases: a comprehensive update J Intern Med 2015 278 369 95 26212387
  69. [71]Sargsyan SA Thurman JM Molecular Imaging of Autoimmune Diseases and Inflammation Mol Imaging 2012 11 7290.2011.00045 22554489
  70. [72]Ley K Laudanna C Cybulsky MI Nourshargh S Getting to the site of inflammation: the leukocyte adhesion cascade updated Nat Rev Immunol 2007 7 678 89 17717539
  71. [73]von Andrian UH Mackay CR T-Cell Function and Migration — Two Sides of the Same Coin. Mackay IR, Rosen FS, Eds N Engl J Med 2000 343 1020 34 11018170
  72. [74]Conti F Priori R Chimenti MS Successful treatment with intraarticular infliximab for resistant knee monarthritis in a patient with spondylarthropathy: A role for scintigraphy with99mTc-infliximab Arthritis Rheum 2005 52 1224 6 15818709
  73. [75]Barrera P Oyen WJG Boerman OC van Riel PLCM Scintigraphic detection of tumour necrosis factor in patients with rheumatoid arthritis Ann Rheum Dis 2003 62 825 8 12922953 PMC1754647
  74. [78]Keelan ET Harrison AA Chapman PT Binns RM Peters AM Haskard DO Imaging vascular endothelial activation: an approach using radiolabeled monoclonal antibodies against the endothelial cell adhesion molecule E-selectin J Nucl Med 1994 35 276 81 7507524
  75. [79]Jamar F Chapman PT Harrison AA Binns RM Haskard DO Peters AM Inflammatory arthritis: imaging of endothelial cell activation with an indium-111-labeled F(ab')2 fragment of anti-E-selectin monoclonal antibody Radiology 1995 194 843 50 7532314
  76. [80]Jamar F Houssiau FA Devogelaer J -P Scintigraphy using a technetium 99m-labelled anti-E-selectin Fab fragment in rheumatoid arthritis Rheumatology 2002 41 53 61 11792880
  77. [81]Marcus C Thakur ML Huynh T V Imaging rheumatic joint diseases with anti-T lymphocyte antibody OKT-3 Nucl Med Commun 1994 15 824 30 7838446
  78. [82]Martins FPP Gutfilen B de Souza SAL Monitoring rheumatoid arthritis synovitis with 99m Tc-anti-CD3 Br J Radiol 2008 81 25 9 18039720
  79. [83]Becker W Emmrich F Horneff G Imaging rheumatoid arthritis specifically with technetium 99m CD4-specific (T-helper lymphocytes) antibodies Eur J Nucl Med 1990 17 156 9 2149102
  80. [84]Malviya G Anzola KL Podestà E 99mTc-labeled Rituximab for Imaging B Lymphocyte Infiltration in Inflammatory Autoimmune Disease Patients Mol Imaging Biol 2012 14 637 46 22127469 PMC3443359
  81. [85]Stevceva L Pavli P Husband AJ Doe WF The inflammatory infiltrate in the acute stage of the dextran sulphate sodium induced colitis: B cell response differs depending on the percentage of DSS used to induce it BMC Clin Pathol 2001 1 3 11580872 PMC57007
  82. [86]Sund M Xu LL Rahman A Qian B-F Hammarstrom M-L Danielsson A Reduced susceptibility to dextran sulphate sodium-induced colitis in the interleukin-2 heterozygous (IL-2+/-) mouse Immunology 2005 114 554 64 15804292 PMC1782116
  83. [87]Kanwar B Gao DW Hwang AB In vivo imaging of mucosal CD4+ T cells using single photon emission computed tomography in a murine model of colitis J Immunol Methods 2008 329 21 30 17964595 PMC2683264
  84. [88]Freise AC Zettlitz KA Salazar FB Immuno-PET in Inflammatory Bowel Disease: Imaging CD4-Positive T Cells in a Murine Model of Colitis J Nucl Med 2018 59 980 5 29326360 PMC6004558
  85. [89]Fang J Nakamura H Maeda H The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect Adv Drug Deliv Rev 2011 63 136 51 20441782
  86. [91]Rowe JM Löwenberg B Gemtuzumab ozogamicin in acute myeloid leukemia: a remarkable saga about an active drug Blood 2013 121 4838 41 23591788
  87. [92]Ansell SM Brentuximab vedotin: delivering an antimitotic drug to activated lymphoma cells Expert Opin Investig Drugs 2011 20 99 105 21121873
  88. [93]Barok M Joensuu H Isola J Trastuzumab emtansine: mechanisms of action and drug resistance Breast Cancer Res 2014 16 209 24887180 PMC4058749
  89. [94]Sun Z Fu Y-X Peng H Targeting tumor cells with antibodies enhances anti-tumor immunity Biophys Reports 2018 4 243 PMC6245233 30533489
  90. [95]Slamon DJ Clark GM Wong SG Levin WJ Ullrich A McGuire WL Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 1987 235 177 82 3798106
  91. [96]Freudenberg JA Wang Q Katsumata M Drebin J Nagatomo I Greene MI The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies Exp Mol Pathol 2009 87 1 19450579 PMC2735009
  92. [97]Loibl S Gianni L HER2-positive breast cancer Lancet 2017 389 2415 29 27939064
  93. [98]Chen W Li X Zhu L Liu J Xu W Wang P Preclinical and clinical applications of specific molecular imaging for HER2-positive breast cancer Cancer Biol Med 2017 14 271 80 28884043 PMC5570603
  94. [99]McLarty K Cornelissen B Scollard DA Done SJ Chun K Reilly RM Associations between the uptake of 111In-DTPA-trastuzumab, HER2 density and response to trastuzumab (Herceptin) in athymic mice bearing subcutaneous human tumour xenografts Eur J Nucl Med Mol Imaging 2009 36 81 93 18712381
  95. [100]Chen K-T Lee T-W Lo J-M In vivo examination of 188Re(I)-tricarbonyl-labeled trastuzumab to target HER2-overexpressing breast cancer Nucl Med Biol 2009 36 355 61 19423002
  96. [101]Sampath L Kwon S Ke S Dual-Labeled Trastuzumab-Based Imaging Agent for the Detection of Human Epidermal Growth Factor Receptor 2 Overexpression in Breast Cancer J Nucl Med 2007 48 1501 10 17785729
  97. [102]Sampath L Kwon S Hall MA Price RE Sevick-Muraca EM Detection of Cancer Metastases with a Dual-labeled Near-Infrared/Positron Emission Tomography Imaging Agent Transl Oncol 2010 3 307 217 20885893 PMC2935634
  98. [103]Kurdziel K Mena E McKinney Y First-in-human phase 0 study of 111In-CHX-A"-DTPA trastuzumab for HER2 tumor imaging J Transl Sci 2018 5 PMC6425962 30906574
  99. [104]Gaykema SBM de Jong JR Perik PJ 111 In-Trastuzumab Scintigraphy in HER2-Positive Metastatic Breast Cancer Patients Remains Feasible during Trastuzumab Treatment Mol Imaging 2014 13 7290.2014.00011 24825298
  100. [105]Wong JYC Raubitschek A Yamauchi D A Pretherapy Biodistribution and Dosimetry Study of Indium-111-Radiolabeled Trastuzumab in Patients with Human Epidermal Growth Factor Receptor 2-Overexpressing Breast Cancer Cancer Biother Radiopharm 2010 25 387 94 20707718 PMC2958439
  101. [106]Dijkers EC Oude Munnink TH Kosterink JG Biodistribution of 89Zr-trastuzumab and PET Imaging of HER2-Positive Lesions in Patients With Metastatic Breast Cancer Clin Pharmacol Ther 2010 87 586 92 20357763
  102. [107]O'Donoghue JA Lewis JS Pandit-Taskar N Pharmacokinetics, Biodistribution, and Radiation Dosimetry for 89 Zr-Trastuzumab in Patients with Esophagogastric Cancer J Nucl Med 2018 59 161 6 28637800 PMC5750520
  103. [108]Tamura K Kurihara H Yonemori K 64Cu-DOTA-Trastuzumab PET Imaging in Patients with HER2-Positive Breast Cancer J Nucl Med 2013 54 1869 75 24029656
  104. [109]Massicano AVF Marquez-Nostra B V Lapi SE Targeting HER2 in Nuclear Medicine for Imaging and Therapy Mol Imaging 2018 17 1536012117745386 29357745 PMC5784567
  105. [110]Nagengast WB de Vries EG Hospers GA In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft J Nucl Med 2007 48 1313 9 17631557
  106. [111]Hoeben BAW Molkenboer-Kuenen JDM Oyen WJG Radiolabeled cetuximab: Dose optimization for epidermal growth factor receptor imaging in a head-and-neck squamous cell carcinoma model Int J Cancer 2011 129 870 8 20957635
  107. [112]Zhou Y Baidoo KE Brechbiel MW Mapping biological behaviors by application of longer-lived positron emitting radionuclides Adv Drug Deliv Rev 2013 65 1098 111 23123291 PMC3593806
  108. [113]Heukelom J Hamming O Bartelink H Adaptive and innovative Radiation Treatment FOR improving Cancer treatment outcomE (ARTFORCE); a randomized controlled phase II trial for individualized treatment of head and neck cancer BMC Cancer 2013 13 84 23433435 PMC3599345
  109. [114]Fleuren EDG Versleijen-Jonkers YMH Heskamp S Theranostic applications of antibodies in oncology Mol Oncol 2014 8 799 812 24725480 PMC5528531
  110. [115]Sickmier EA Kurzeja RJM Michelsen K Vazir M Yang E Tasker AS The Panitumumab EGFR Complex Reveals a Binding Mechanism That Overcomes Cetuximab Induced Resistance PLoS One 2016 11 e0163366 27658254 PMC5033319
  111. [116]Aghevlian S Lu Y Winnik MA Hedley DW Reilly RM Panitumumab Modified with Metal-Chelating Polymers (MCP) Complexed to 111 In and 177 Lu—An EGFR-Targeted Theranostic for Pancreatic Cancer Mol Pharm 2018 15 1150 9 29314858
  112. [117]Bernhard W El-Sayed A Barreto K Gonzalez C Fonge H Geyer CR Near infrared imaging of epidermal growth factor receptor positive xenografts in mice with domain I/II specific antibody fragments Theranostics 2019 9 974 85 30867810 PMC6401412
  113. [118]Tsai WK Zettlitz KA Tavaré R Kobayashi N Reiter RE Wu AM Dual-Modality ImmunoPET/Fluorescence Imaging of Prostate Cancer with an Anti-PSCA Cys-Minibody Theranostics 2018 8 5903 14 30613270 PMC6299441
  114. [119]Heskamp S van Laarhoven HWM Molkenboer-Kuenen JDM ImmunoSPECT and immunoPET of IGF-1R expression with the radiolabeled antibody R1507 in a triple-negative breast cancer model J Nucl Med 2010 51 1565 72 20847162
  115. [120]Yap ML McFadyen JD Wang X Targeting Activated Platelets: A Unique and Potentially Universal Approach for Cancer Imaging Theranostics 2017 7 2565 74 28819447 PMC5558553
  116. [121]Fleuren EDG Versleijen-Jonkers YMH van de Luijtgaarden ACM Predicting IGF-1R Therapy Response in Bone Sarcomas: Immuno-SPECT Imaging with Radiolabeled R1507 Clin Cancer Res 2011 17 7693 703 22038993 PMC3243810
  117. [122]Trebeschi S Drago SG Birkbak NJ Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers Ann Oncol 2019 30 998 1004 PMC6594459 30895304
  118. [123]Shi Y Lammers T Combining Nanomedicine and Immunotherapy Acc Chem Res 2019 52 1543 54 31120725 PMC7115879
  119. [124]Xu M Han Y Liu G Preclinical Study of a Fully Human Anti-PD-L1 Antibody as a Theranostic Agent for Cancer Immunotherapy Mol Pharm 2018 15 4426 33 30133286
  120. [125]Lusis AJ Atherosclerosis Nature 2000 407 233 41 11001066 PMC2826222
  121. [127]Nishi K Itabe H Uno M Oxidized LDL in Carotid Plaques and Plasma Associates With Plaque Instability Arterioscler Thromb Vasc Biol 2002 22 1649 54 12377744
  122. [128]Torzewski M Shaw PX Han K-R Reduced In vivo Aortic Uptake of Radiolabeled Oxidation-Specific Antibodies Reflects Changes in Plaque Composition Consistent With Plaque Stabilization Arterioscler Thromb Vasc Biol 2004 24 2307 12 15528482
  123. [129]Briley-Saebo KC Nguyen TH Saeboe AM In vivo detection of oxidation-specific epitopes in atherosclerotic lesions using biocompatible manganese molecular magnetic imaging probes J Am Coll Cardiol 2012 59 616 26 22300697 PMC3333483
  124. [130]Wen S Liu D-F Cui Y In vivo MRI detection of carotid atherosclerotic lesions and kidney inflammation in ApoE-deficient mice by using LOX-1 targeted iron nanoparticles Nanomedicine Nanotechnology, Biol Med 2014 10 639 49 24103305
  125. [131]Hayashida K Kume N Murase T Serum Soluble Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1 Levels Are Elevated in Acute Coronary Syndrome Circulation 2005 112 812 8 16061745
  126. [132]Kaufmann BA Carr CL Belcik JT Molecular Imaging of the Initial Inflammatory Response in Atherosclerosis Arterioscler Thromb Vasc Biol 2010 30 54 9 19834105 PMC2814530
  127. [133]Davidson BP Kaufmann BA Belcik JT Xie A Qi Y Lindner JR Detection of Antecedent Myocardial Ischemia With Multiselectin Molecular Imaging J Am Coll Cardiol 2012 60 1690 7 23021335 PMC3856914
  128. [134]Yan F Sun Y Mao Y Ultrasound Molecular Imaging of Atherosclerosis for Early Diagnosis and Therapeutic Evaluation through Leucocyte-like Multiple Targeted Microbubbles Theranostics 2018 8 1879 91 29556362 PMC5858506
  129. [135]Myers DD Hawley AE Farris DM P-selectin and leukocyte microparticles are associated with venous thrombogenesis J Vasc Surg 2003 38 1075 89 14603220
  130. [136]Fernandes LFB Fregnani JHTG Strunz CMC de Andrade Ramos Nogueira A Longatto-Filho A Role of P-selectin in thromboembolic events in patients with cancer Mol Clin Oncol 2018 8 188 96 29387414 PMC5769283
  131. [137]Kaufmann BA Carr CL Belcik JT Molecular imaging of the initial inflammatory response in atherosclerosis: implications for early detection of disease Arterioscler Thromb Vasc Biol 2010 30 54 9 19834105 PMC2814530
  132. [138]Oliveira BL Caravan P Peptide-based fibrin-targeting probes for thrombus imaging Dalt Trans 2017 46 14488 508 PMC5684589 29051933
  133. [139]Hara T Ughi GJ McCarthy JR Intravascular fibrin molecular imaging improves the detection of unhealed stents assessed by optical coherence tomography in vivo Eur Heart J 2015 38 447 55 26685129 PMC5837565
  134. [140]Lohrke J Siebeneicher H Berger M 18F-GP1, a Novel PET Tracer Designed for High-Sensitivity, Low-Background Detection of Thrombi J Nucl Med 2017 58 1094 9 28302764
  135. [141]Kim C Lee JS Han Y Glycoprotein IIb/IIIa Receptor Imaging with 18 F-GP1 PET for Acute Venous Thromboembolism: An Open-Label, Nonrandomized, Phase 1 Study J Nucl Med 2019 60 244 9 PMC8833852 29959214
  136. [142]Wang X Gkanatsas Y Palasubramaniam J Thrombus-Targeted Theranostic Microbubbles: A New Technology towards Concurrent Rapid Ultrasound Diagnosis and Bleeding-free Fibrinolytic Treatment of Thrombosis Theranostics 2016 6 726 38 27022419 PMC4805666
  137. [143]Tarkin JM Dweck MR Evans NR Imaging Atherosclerosis Circ Res 2016 118 750 69 26892971 PMC4756468
  138. [144]Anwaier G Chen C Cao Y Qi R A review of molecular imaging of atherosclerosis and the potential application of dendrimer in imaging of plaque Int J Nanomedicine 2017 12 7681 93 29089763 PMC5656339
  139. [145]Broisat A Hernot S Toczek J Nanobodies targeting mouse/human VCAM1 for the nuclear imaging of atherosclerotic lesions Circ Res 2012 110 927 37 22461363 PMC3918224
  140. [146]Lindner JR Sinusas A Molecular imaging in cardiovascular disease: Which methods, which diseases? J Nucl Cardiol 2013 20 990 1001 24092271 PMC3943209

Cited by

Sorted by citations

Authors
Dammes, N., & Peer, D.
Affiliations
Tel Aviv University (IL)
Corresponding author
Peer, Dan
ORCID
Peer, Dan
Venue
Theranostics
Publisher
Ivyspring International Publisher
Published
2020
Volume
10
Issue
2
Pages
938-955
ISSN
1838-7640 (ISSN-L)
DOI
10.7150/thno.37443
PMC
PMC6929980
OpenAlex
W2993405303
Cited by
138
References
2
Citations by year
2026: 7 · 2025: 24 · 2024: 19 · 2023: 21 · 2022: 24 · 2021: 30 · 2020: 13
FWCI
2.51
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Theranostics (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
H2020 European Research Council (647410)
Topics
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Monoclonal and Polyclonal Antibodies Research
Keywords
monoclonal antibodies, molecular imaging, radionuclide targeting, imaging agents, autoimmune disease, tumor imaging, cardiovascular imaging, precision medicine, treatment response prediction
MeSH terms
Antineoplastic Agents, Immunological, Animals, Antibodies, Monoclonal, Autoimmune Diseases, Cardiovascular Diseases, Humans, Neoplasms, Molecular Imaging, Precision Medicine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review